References

Cure Arthritis Naturally

Beat Arthritis Naturally

Get Instant Access

1 Rose NR: Foreword - The uses of autoantibodies. In: Autoantibodies (Eds: Shoenfeld Y and Peter JB), Amsterdam: Elsevier, Amsterdam 1996, p. xxvii-xxixv.

2 Criswell LA: Familial clustering of disease features: Implications for the etiology and investigation of systemic autoimmune diseases. Arthritis Rheum 2004; 50:1707-1708.

3 Rarok AA, van der Geld Y, Stegeman CA, Limburg PC, Kallenberg CGM: Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using biosensor technology. J Clin Immunol 2003; 23:460-468.

4 Takeda I, Rayno K, Wolfson-Reichlin M, Reichlin M: Heterogeneity of anti-dsDNA antibodies in their cross-reaction with ribosomal P proteins. J Autoimmun 1999; 13:423-428.

5 Zhao Z, Weinstein E, Tuzova M, Davidson A, Mundel P, Marambio P, Putter-man C: Cross-reactivity of human lupus anti-DNA antibodies with a-actinin and nephritogenic potential. Arthritis Rheum 2005; 52:522-530.

6 Greidinger EL, Casciola-Rosen L, Morris SM, Hoffman RW, Rosen A: Autoanti-body recognition of distinctly modified forms of the U1-70-kd antigen is associated with different clinical disease manifestations. Arthritis Rheum 2000; 43:881-888.

7 Reveille JD: Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep 2003; 5:160-167.

8 Tan FK, Arnett FC, Reveille JD, Ahn C, Antohi S, Sasaki T, Nishioka K, Bona CA: Autoantibodies to fibrillin 1 in systemic sclerosis. Ethnic differences in antigen recognition and lack of correlation with specific clinical features or

HLA alleles. Arthritis Rheum 2000; 43:2464-2471.

9 Cooper GS, Parks CG, Treadwell EL, StClair EW, Gilkeson GS, Cohen PL, Roubey RAS, Dooley MA: Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002; 11:161-167.

10 Wang J, Satoh M, Kabir F, Shaw M, Domingo MA, Mansoor R, Behney KM, Dong X, Lahita RG, Richards HB, Reeves WH: Increased prevalence of autoantibodies to Ku antigen in African American versus white patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:2367-2370.

11 Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA, Wright TM: Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA to-poisomerase I antibody. Arthritis Rheum 1999; 42:365-474.

12 Tormey VJ, Bunn CC, Denton CP, Black CM: Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001; 40:1157-1162.

13 Lee SS, Lawton JWM: Heterogeneity of anti-PR3 associated disease in Hong Kong. Postgrad Med J 2000; 76:287-288.

14 Takeuchi F, Nabeta H, Füssel M, Conrad K, Frank KH: Association of the TNFa13 microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis 2000; 59:293-296.

15 Airbuckle MR, McClain MT, Rubertone MV, Scofield H, Dennis GJ, James JA, Harley JB: Development of autoantibod-ies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526-1533.

16 Waltuck J, Buyon JP: Autoantibody-asso-ciated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120:544-551.

17 Julkunen H, Eronen M: Long-term outcome of mothers of children with isolated heart block in Finland. Arthritis Rheum 2001; 44:647-652.

18 Del Puente A, Knowler WC, Pettitt DJ, Bennett PH: The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988; 31:12391244.

19 Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT, Habibuw MR, Vandenbroucke JP, Dijk-mans BAC: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380-386.

20 Rantapää-Dahlqvist S, de Jong BAW, Ber-glin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-2749.

21 Iijima T, Tada H, Hidaka Y, Yagoro A, Mitsuda N, Kanzaki T, Murata Y, Amino N: Prediction of postpartum onset of rheumatoid arthritis. Ann Rheum Dis 1998; 57:460-463.

22 Tramposch HD, Smith CD, Senecal JL, Rothfield NF: A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984; 27:121-124.

23 Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, Roussin A, Earnshaw W, Rothfield NF: Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. Arthritis Rheum 1991; 34:68-77.

24 Conrad K, Mehlhorn J: Diagnostic and prognostic relevance of autoantibodies in uranium miners. Int Arch Allergy Immunol 2000; 123:77-91.

25 Satoh M, Miyazaki K, Mimori T, Akizuki M, Ichikawa Y, Homma M, Ajimani AK, Reves WH: Changing autoantibody pro files with variable clinical manifestations in a patient with relapsing systemic lupus erythematosus and polymyositis. Br J Rheumatol 1995; 34:915-919.

26 Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ: Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47:634-641.

27 Wiik AS, Gordon TP, Kavanaugh AF, Lahita RG, Reeves W, van Venrooij WJ, Wilson MR, Fritzler M, and the IUIS/ WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases: Cutting Edge Diagnostics in Rheumatology: The Role of Patients, Clinicians, and Labora-tor Scientists in Optimizing the Use of Autoimmune Serology. Arthritis Rheum 2004; 51:291-298.

28 Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004; 34:501-537.

29 Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander HL, Car-sons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weis-man HM: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-558.

30 Zandbelt MM, Vogelzangs J, van de Putte LBA, van Venrooij WJ, van den Hoogen FHJ: Anti-fodrin antibodies do not add much to the diagnosis of Sjögren's syndrome. Arthritis Res Ther 2004; 6:R33-R38.

31 Bacman S, Sterin-Borda L, Camusso JJ, Arana R, Hubscher O, Borda E: Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome. Clin Exp Immunol 1996; 104:454-459.

32 Naito Y, Matsumoto I, Wakamatsu E, Goto D, Sugiyama T, Matsumura R, Ito S, Tsutsumi A, Sumida T: Muscarinic acetylcholine receptor autoantibodies in patients with Sjogren's syndrome. Ann Rheum Dis 2005; 64:510-511.

33 Masi AT, Rodnan GP, Medsger TA, et al. (Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee): Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-590.

34 LeRoy EC, Medsger TA Jr: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28:1573-1576.

35 Poormoghim H, Lucas M, Fertig N, Medsger TA Jr: Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43:444-451.

36 LeRoy EC, Black C, Fleichmajer R, Ja-blonska S, Krieg T, Medsger TA Jr, Ro-well N, Wollheim F: Scleroderma (systemic sclerosis). Classification, subset and pathogenesis. J Rheumatol 1988; 15:202-205.

37 Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M: Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986; 13:911-916.

38 Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G: Systemic sclerosis. Demographic, clinical and serologic features and survival in 1,012 Italian patients. Medicine 2002; 81:139-153.

39 Scussel-Lonzetti L, Joyal F, Raynauld J-P, Roussin A, Rich E, Goulet JR, Raymond Y, Senecal JL: Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002; 81:154-167.

40 Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF: Clinical association of anticentromere antibodies and antibodies to topoiso-merase I. A study of 355 patients. Arthritis Rheum 1988; 31:378-385.

41 Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ: Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999; 117:395-402.

42 Cepeda EJ, Reveille JD: Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and releance. Curr Opin Rheumatol 2004; 16:723-732.

43 Pollard KM, Lee DK, Casiano CA, Blüth-ner M, Johnston MM, Tan EM: The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibril-larin and modifies its molecular and antigenic properties. J Immunol 1997; 158:3521-3528.

44 Phan TG, Cass A, Gillin A, Trew P, Fertig N, Sturgess A: Anti-RNA polymerase III antibodies in the diagnosis ofsclero-derma renal crisis sine scleroderma.

J Rheumatol 1999; 26:2489-2492.

45 Bohan A, Peter JB: Polymyositis and der-matomyositis (first of two parts). N Engl J Med 1975; 292:344-347.

46 Hengstman GJD, van Engelen BGM, van Venrooij WJ: Myositis specific autoantibodies: changing insights in patho-physiology and clinical associations. Curr Opin Rheumatol 2004; 16:692-699.

47 Imbert-Masseau A, Hamidou M, Agard C, Grolleau J-Y, Cherin P: Antisynthetase Syndrome. Joint Bone Spine 2003; 70:161-168.

48 Miller T, Al-Lozi MT, Lopate G, Pestronk A: Myopathy with autoantibodies to the signal recognition particle: clinical and pathological features. J Neurol Neuro-surg Psychiatry 2002; 73:420-428.

49 Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW: A new approach to the classification of idio-pathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70:360-374.

50 Hengstman GJD, Brouwer R, Vree Egberts WTM, Seelig HP, Jongen PJH, van Venroiij WJ, van Engelen BGM: Clinical and serological characteristics of125 Dutch myositis patients. Myositis specific autoantibodies aids in the differential diagnosis ofthe idiopathic inflammatory myopathies. J Neurol 2002; 249:69-75.

51 Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR: Mixed connective tissue disease - an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52:148-159.

52 Reichlin M, Maddison PJ, TargoffI, Bunch T, Arnett F, Sharp G, Treadwell E, Tan EM: Antibodies to a nuclear/nu-cleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984; 4:40-44.

53 Blaszczyk M, Jablonska S, Szymanska-Jagiello W, Jarzabek-Chorzelska M, Chorzelski T, Mohamed AH: Childhood scleromyositis: an overlap syndrome associated with PM-Scl antibody. Pediatric Dermatol 1991; 8:1-8.

54 Wilson WA, Gharavi AE, Koike T, Lock-shin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GRV, Tri-plett DA, Khamashta MA: International consensus statement on preliminary classification for definite antiphospho-lipid syndrome. Arthritis Rheum 1999; 42:1309-1311.

55 Hughes GRV, Harris EN, Gharavi AE: The antiphospholipid syndrome. J Rheu-matol 1986; 13:486-489.

56 Asherson RA, Cervera R: The antiphos-pholipid syndrome: multiple faces beyond the classical presentation. Autoim-munity Rev 2003; 2:140-151.

57 Obermoser G, Bitterlich W, Kunz F, Sepp NT: Clinical significance of anticardiolipin and anti-jS2-glycoprotein I antibodies. Int Arch Allergy Immunol 2004; 135:148-153.

58 Sairam S, Baethge BA, McNearney T: Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies. Clin Rheumatol 2003; 22:24-29.

59 Atsumi T, Koike T: Clinical relevance of prothrombin antibodies. Autoimmun Rev 2002; 1:49-53.

60 Falk RJ, Jennette JC: Anti-neutrophil cy-toplasmic autoantibodies with specificity for myeloperoxidase in patients with sys temic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988; 318:1651-1657.

61 Jenne DE, Tschopp J, Lüdemann J, Utecht B, Gross WL: Wegener's autoantigen decoded. Nature 1990; 346:520.

62 Conrad K, Schößler W, Hiepe F: Autoantibodies in Systemic Autoimmune Diseases. A Diagnostic Reference. Pabst Science Publishers, Lengerich 2002.

63 Choi HK, Merkel PA, Walker AM, Niles JL: Drug-associated antineutrophil cyto-plasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43:405-413.

64 Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS: Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004; 43:906-914.

65 Steen V, Medsger TA Jr: Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48:516-522.

66 Harris ML, Rosen A: Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoanti-bodies. Curr Opin Rheumatol 2003; 15:778-784.

67 Hénault J, Tremblay M, Clément I, Raymond Y, Senécal JL: Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004; 50:3265-3274.

68 Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, Sato S: Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004; 138:357-363.

69 Alessandri C, Bombardieri M, Scrivo R, Viganego F, Conti F: Anti-carbonic anhy-drase II antibodies in systemic sclerosis: association with lung involvement. Auto-immunity 2003; 36:85-89.

Was this article helpful?

0 0
Natural Arthritis Pain Remedies

Natural Arthritis Pain Remedies

It's time for a change. Finally A Way to Get Pain Relief for Your Arthritis Without Possibly Risking Your Health in the Process. You may not be aware of this, but taking prescription drugs to get relief for your Arthritis Pain is not the only solution. There are alternative pain relief treatments available.

Get My Free Ebook


Post a comment